Moffitt logo

Clinical Trials Search

Clinical Trial 19648

Cancer Type: Neurologic Oncology
Study Type: Treatment
NCT#: NCT03719768

Phase: Phase I
Prinicipal Investigator:

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Phase IB Study of Avelumab with Radiotherapy in Patients with Leptomeningeal Disease

Summary

This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.

Objective

Objectives: Primary Objectives: To establish the safety of combination of Avelumab and WBRT in patients with LMDz and perform exploratory analysis of the patient survival rate. Secondary Objectives: To gather preliminary data regarding clinical outcomes of the study therapy Endpoints: Primary Endpoints: 1) Safety and dose limiting toxicities. 2) The proportion of patients surviving at least 15 weeks after the first dose of Avelumab. Secondary Endpoints: 1) The number and activation status of T cells and the CSF cytokine activation profile in the CSF (relative to serum and relative to collection time), measured before and after Avelumab administration; 2) LMDz/central nervous system response rate and systemic (i.e., non-central nervous system) response rates; 3) the association between serum/CSF levels of Avelumab/activated T-cell responses and clinical toxicities and responses; 4) overall survival and progression-free survival; 5) the association between enumerated CSF circulating tumor cells, conventional CSF cytology, and response rates; 6) evolution of clinical status associated with the cardinal CSF biomarkers; and 7) levels of Avelumab in the serum and CSF.

Treatments

Therapies

Medications

Avelumab (); MSB00100718C (Avelumab)

Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of any cancer except leukemia. Patients must have the presence of malignant cells in the CSF (CSF+) OR at least 2 of the 3 following features: 1) clinical signs and symptoms of LMDz 2) characteristic radiographic abnormalities (see below), and 3) ¿suspicious¿ CSF (Chamberlain 2017)
  • Patients must have an Eastern Cooperative Oncology Group performance scale of ≤ 3
  • An interval of at least 2 weeks after the end of prior radiation therapy to the brain (e.g., stereotactic radiosurgery or other¿exclusions apply) and fulfill criteria listed in section 8.2 under Tumor Biospecimens
  • An interval of at least 4 weeks following any surgical resection of brain lesions prior to treatment
  • An interval of at least 4 weeks after the last administration of any investigational agent, bevacizumab, immunotherapy, or prior cytotoxic agents
  • Be ≥ 18 years of age on the day of signing consent
  • Demonstrate adequate organ function as defined in protocol. All screening labs should be performed with 14 days of treatment initiation
  • Resting baseline O2 saturation by pulse oximetry of ≥ 92% at rest
  • Patients must have recovered from the toxic effects of prior therapies (≤ Grade 1)
  • Provision of signed and dated informed consent form
  • Life expectancy of ≥ 8 weeks
  • Pregnancy test: negative serum or urine pregnancy test at screening for women of childbearing potential.
  • Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last Avelumab treatment administration, if the risk of conception exists.

  • Exclusion Criteria

  • Receiving other treatments specifically administered to treat LMDz or antibody based therapies within the last 4 weeks. However, patients receiving concomitant non-cytotoxic therapy (hormonal or cytostatic therapy) to control systemic disease or bulk CNS disease will be eligible, provided the therapy is not a phase I agent, an agent which significantly penetrates the CSF (e.g., high-dose methotrexate, thiotepa, or high-dose ara-C), or an agent known to have serious unpredictable CNS side effects. Careful documentation of concurrently administered systemic drugs is required.
  • Patients with a ventriculoperitoneal or ventriculoatrial shunt must have an on/off device in their shunt systems to be eligible for the study. Patients must be able to tolerate shunt closure for ~4 hours without development of clinical signs of increased intracranial pressure. Patients unable to tolerate shunt closure for ~4 hours will not be eligible for the study.
  • Unable or unwilling to have a contrast-enhanced brain MRI.
  • Currently participating in or having participated in a study of an investigational agent or device ≤ 4 weeks prior to the first dose of study treatment.
  • Currently participating in or having participated in a study of an investigational agent or use of an investigational device within 4 weeks of the first dose of treatment.
  • Near physiologic doses of steroid therapy (≤ 2 mg/day dexamethasone equivalents) are allowed.
  • Prior chemotherapy or targeted small molecule therapy within 4 weeks prior to study Day 1 or nonrecovery (i.e., 4 weeks earlier.
  • Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  • Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen¿s syndrome will not be excluded from the study.
  • Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on study.
  • Requires escalating or chronic supraphysiologic doses of corticosteroids (> 10 mg/day prednisone equivalents).
  • Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject¿s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. > Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 90 days after the last dose of trial treatment.
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti- Cytotoxic T-lymphocyte-associated antigen-4 (cTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • Other exclusions apply

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.